Wealthspire Advisors LLC Purchases 160 Shares of ICU Medical, Inc. (NASDAQ:ICUI)

Wealthspire Advisors LLC boosted its position in ICU Medical, Inc. (NASDAQ:ICUI) by 6.4% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 2,660 shares of the medical instruments supplier’s stock after purchasing an additional 160 shares during the quarter. Wealthspire Advisors LLC’s holdings in ICU Medical were worth $413,000 at the end of the most recent quarter.

Other institutional investors have also added to or reduced their stakes in the company. Barclays PLC raised its holdings in ICU Medical by 15.6% in the third quarter. Barclays PLC now owns 59,207 shares of the medical instruments supplier’s stock worth $10,790,000 after purchasing an additional 8,010 shares in the last quarter. LMR Partners LLP bought a new position in ICU Medical in the third quarter worth $3,884,000. Principal Financial Group Inc. raised its holdings in ICU Medical by 24.6% in the third quarter. Principal Financial Group Inc. now owns 126,937 shares of the medical instruments supplier’s stock worth $23,130,000 after purchasing an additional 25,031 shares in the last quarter. MetLife Investment Management LLC raised its holdings in ICU Medical by 129.1% in the third quarter. MetLife Investment Management LLC now owns 12,389 shares of the medical instruments supplier’s stock worth $2,258,000 after purchasing an additional 6,981 shares in the last quarter. Finally, Jennison Associates LLC bought a new position in ICU Medical in the fourth quarter worth $556,000. Institutional investors own 96.10% of the company’s stock.

Insider Buying and Selling

In related news, CEO Vivek Jain sold 12,000 shares of ICU Medical stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $162.91, for a total value of $1,954,920.00. Following the completion of the sale, the chief executive officer now directly owns 104,593 shares in the company, valued at approximately $17,039,245.63. This trade represents a 10.29 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 6.70% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on the company. KeyCorp increased their price objective on ICU Medical from $198.00 to $209.00 and gave the stock an “overweight” rating in a report on Wednesday, November 13th. Jefferies Financial Group upgraded ICU Medical from a “hold” rating to a “buy” rating and set a $200.00 price target for the company in a report on Wednesday, December 11th. StockNews.com upgraded ICU Medical from a “hold” rating to a “buy” rating in a report on Wednesday, November 20th. Finally, Needham & Company LLC restated a “hold” rating on shares of ICU Medical in a report on Wednesday, November 13th. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $199.67.

ICU Medical Price Performance

NASDAQ ICUI opened at $154.27 on Thursday. ICU Medical, Inc. has a one year low of $93.36 and a one year high of $196.26. The stock has a 50-day moving average of $160.70 and a 200 day moving average of $166.21. The company has a market capitalization of $3.78 billion, a price-to-earnings ratio of -33.76 and a beta of 0.63. The company has a debt-to-equity ratio of 0.75, a quick ratio of 1.03 and a current ratio of 2.29.

About ICU Medical

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.